Flexus founders regroup after $1.25B Bristol-Myers deal

Flexus Biosciences turned heads around the industry when Bristol-Myers Squibb ($BMY) signed a $1.25 billion deal to buy the fledgling biotech in February, but the company's founders aren't resting on their laurels, turning around with immediate plans for a new startup. The acquisition included terms that allowed Flexus' brain trust to spin out cancer candidates into new companies, and, as Chemical & Engineering News reports, founders Terry Rosen and Juan Jaen are wasting no time with that process, beginning an effort they hope can churn out one new project each year. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.